Consensus document on nosocomial pneumonia;Documento de consenso sobre pneumonia nosocomial

Revista Portuguesa de Pneumologia

Volumn 13, Issue 3, 2007, Pages 419-486

  Froes, Filipe ^a   Paiva, José Artur ^b   Amaro, Piedade ^b   Baptista, João Pedro ^b   Brum, Gabriela ^b   Bento, Henrique ^b   Duarte, Paula ^b   Dias, Conceição Sousa ^b   Glória, Carlos ^b   Estrada, Helena ^b   Telo, Luís ^b   Silva, Eduardo ^b   Pereira, João Gonçalves ^b   do Carmo, Germano ^b  

^a Portuguese Intensive Care Society   (Portugal)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; CORTICOSTEROID; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; NETILMICIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; DRUG PENETRATION; EVIDENCE BASED MEDICINE; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LEGIONELLA; LOADING DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 34547461758     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s2173-5115(07)70346-9     Document Type: Note

References (127)

1. American Thoracic Society Documents. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated pneumonia. Am J Respir Ctit Care Med 2005; 171:388-416.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-92.
3. Campbell G, Niederman M, Broughton W, Craven D, Fein A, Fink M, et al. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society. Am J Respir Crit Care Med 1996;153:1711-25.
4. Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, Correa H, Diaz E, Garnacho J, Llorio M, Rios M, Rodriguez A, Solé-Violan. International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-Associated Pneumonia. Chest 2001;120:955-70.
5. Jordà R, Torres A, Ariza FJ, Álvarez-Lerma F, Barcenilla F, et al. Recomendaciones para el tratamiento de la pneumonia intrahospitalaria grave. Arch Bronconeumol 2004;40-518-33.
6. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
7. Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factores of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990;142:523-28.
8. Rello J, Ollendorf DA, Oster G, Montserrat V, Bellm L, Redman R, Kollef MR. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-21.
9. Heyland DK, Cook DJ, Griffith L, et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critical ill patient. Am J Respir Crit Care Med 1999;159:1249-1256.
10. El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163:645-51.
11. El Solh AA, Aquilina AT, Dhillon RS, Ramadan F, Nowak P, Davies J. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older peoplewith severe pneumonia. Am J Respir Crit Care Med 2002;166:1038-43.
12. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative evaluation usind immediate post moprtem biopsies. Thorax 1999;54: 867-73.
13. Delclaux C, Roupie E, Blot F, Brochard L, Lemaire F, Brun-Buisson C. Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis. Am J Respir Crit Care Med. 1997;156:1092-8
14. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
15. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-8.
16. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22:387-94.
17. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;132:621-30.
18. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588-98.
19. Heyland DK, Cook DJ, Marshall J, Heule M, Guslits B, Lang J, Jaeschke R. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia. Canadian Critical Care Trials Group. Chest. 1999115:1076-84.
20. Kirtland SH, Corley DE, Winterbauer RH, Spring-meyer SC, Casey KR, Hampson NB, Dreis DF. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest 1997;112:445-57.
21. Wermert D, Marquette CH, Copin MC, Wallet F, Fraticelli A, Ramon P, Tonnel AB. Influence of pulmonary bacteriology and histology on the yield of diagnostic procedures in ventilator-acquired pneumonia. Am J Respir Crit Care Med 1998;158:139-47.
22. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jarlier V, Le Charpentier Y, Grosset J, Viars P. Nosocomial bronchopnemonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992,146:1059-66.
23. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and non-bronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9.
24. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11.
25. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676-82.
26. Fartoukh M, Maître B, Honoré S, et al. Diagnosing pneumonia during mechanical ventilation. The Clinical Pulmonary Infection Score Revisited. Am J Respir Crit Care Med 2003;168:173-79.
27. Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Resp Crit Care Med 1995;152:1982-91.
28. Franklin C, et al. Reduced mortality of pneumococcal bacteremia after early intensive care. J Intensive Care 1994;6: 302-7.
29. Niederman M. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. Semin Respir Infect 1990 Sep;5(3):173-84.
30. Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC, Gibert C, Chastre J. Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:41-6.
31. ERS Task Force. Ventilator-associated pneumonia. Ent Respir J 2001;17:1034-45.
32. Luna C, Videla A, Mattera J, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999;116:1075-84.
33. Tablan OC, et al. Guidelines for preventing health-care-associated pneumonia: recomendations of the CDC and the Health-care Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53 (RR03):10-13.
34. Kolief MH, Sherman G, Ward S, et al. Inadequate anti-microbial. treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115-462-474.
35. Kollef M, Ward S. The Influence of Mini-BAL Cultures on Patient Outcomes. Implications for the Antibiotic Management of Ventilator-Associated Pneumonia, Chest 1998; 113:412-20.
36. Weinstein M, Towns M, Quartey S, et al. The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults. CID 1997;24:584-602.
37. Paepe PD, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-51.
38. Pereira JG. Andbioterapia na pneumonia: A emergência das resistências. Revista de Infecções Respiratŕias 2005; 1: 4-12.
39. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator associated pneumonia. Crit Care Med 2001;29:1109-15.
40. Sieger B, Berman SJ, Geckler R, Farkas S. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Crit Care Med 1997; 25:1663-70.
41. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia Crit Care Med 2004; 32: 2183-2190.
42. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventdator-associated pneumonia. Chest 2004; 125:1791-1799.
43. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-96.
44. Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004; 24: 477-502.
45. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003; 17: 479-501.
46. Isada CM, Kasten BL, Goldman MP, Gray LD, Aberg JA, Infections diseases handbook. 5th edition. Lexi-Comp. 2003.
47. Pereira JG. Antibióticos em perfusão contínua. Revista Portuguesa de Medicina Intensiva 2004; 13: 15-9.
48. Leder K, Turnidge JD, Korman TM Grayson ML. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. Journal of Andmicrobial Chemotherapy 1999; 43: 113-8.
49. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22: 471-83.
50. Lipmana J, Gomersallb CD, Ginc T, Joyntb GM, Youngb RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrobial Chemotherapy 1999; 43: 309-11.
51. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong ELY, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrobial Chemotherapy 2001; 47: 421-9.
52. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agent Chemother 1999; 43: 2559-61.
53. Li J, Nation R, Turnidge J, Milne R, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6: 589-601.
54. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am 2003;17:503-28.
55. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: Pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin N Am 2003; 17: 54562.
56. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agent Chemother 2001; 45: 781-5.
57. Wyncoll DL, Bowry R, Giles LJ. Antibiotics in continuous infusion: Time for re-evaluation? In: Vincent JL (Ed.). Year Book of Intensive Care and Emergency Medicine. Springer, New York 2002: 398-406.
58. Rello J, Ausina V, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-5.
59. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9.
60. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139:877-84.
61. Rello J, Quintana E, Ausina V, et al. Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991; 100:439-44.
62. Brewer SC, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109: 1019-29.
63. Leroy O, Jaffré S, d'Ecrivan T, et al. Hospital-Acquired Pneumonia. Risk factors for antimicrobial-resistant causative pathogens in critically ill patients. Chest 2003;123:2034-42.
64. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interaction in Pseudominas aeruginosa Pneumonia. Am J Respir Crit Care Med. 2005;171:1209-23.
65. Chatzinikoloau I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 24 episodes. Arch Intern Med 2000;160:501-9.
66. Chastre J, Trouillet JL. Problem pathogens Pseudomonas aeruginosa and Acinetobacter. Semin Respire Infect 2000;15;287-98.
67. Vidal F, Mens J, Martinez JA, et al. Pseudomonas aeruginosa bacteremia in patients infected with HIV-1. Eur J Clin Microbiol Infect Dis 1999;18: 473-7.
68. Rello J, Ausina V, Ricart M, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20:193-8.
69. Sopena N, Sabria M, Pedro-Botet ML, et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999; 18:852-8.
70. Aranciba F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa. Arch Intern Med 2002;162:1849-58.
71. Groenewegen KH, et al. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 2003; 97:770-7.
72. Nseir S, Pompeo C, Soubrier S, et al. Impact of Ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005; 128:1650-6.
73. Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of patients with early-onset versus late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-42.
74. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-13
75. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
76. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150:1545-49.
77. Rello J, Quintana E, Ausina V, et al. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990;142:1320-4.
78. Solomkin JS, Bjornson HS, Cainzos M, et al. A consensus statement on empiric therapy for suspected grampositive infections in surgical patients. Am J Surgery 2004;187:134-145.
79. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. Journal Clinical Pharmacy Therapeutics 2004; 29:351-7.
80. Pereira JM, Azevedo A, Paiva JA. Continuous infusion of vancomycin: is it a step forward in vancomycin therapy? Intensive Care Med 2005; 31; Suppl 1: S222.
81. Wysocki M, Delatour F, Faurisson F, Rauss A et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Andmicrob, Agents Chemother 2001; 45:2460-7
82. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.
83. Garnacho-Montero J, Ortiz-Leyva C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparision with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
84. Baraibar J, Correa H, Mariscal D, et al. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest 1997; 112:1050-4.
85. Mahgoub S et al. Underlying characteristics of patients harbouring higly resistant Acinetobacter baumannii. Am J Infect Control 2002;30:386-90.
86. Rodriguez-Baño, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004; 825-31.
87. Ayan M, et al. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter infection in a teaching hospital. J Infect 2003;54:39-45.
88. Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998; 129:182-9.
89. Corbella X, Pujol M, Ayats J, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis 1996; 23:329-34.
90. Lortholary O, Fagon J-Y, Hoi AB, et al.. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20:790-6.
91. Tablan OC, et al. Guidelines for preventing health-care-associated pneumonia: recomendations of the CDC and the Health-care Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53 (RR03):1-36.
92. Ebiary M, Sarmiento X, Torres A, Nogue S, Mesalles E, Bodi M, Almirall J. Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 1997;156:1467-72.
93. Tkatch Ls, Kusne S, WD I, et al. Epidemiology of legionella pneumonia and factors associated with legionella-related mortality at a terciary care center. Clin Infect Dis 1998;27:1479-86.
94. Carratala J, Gudiol F, Pallares R, et al. Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med 1994;149:625-9.
95. Le Saux NM, Sekla L, McLeod J, Parker S, Rush D, Jeffery JR, Brunham RC. Epidemic of nosocomial Legionnaires' disease in renal transplant recipients: a case-control and environmental study. Can Med Assoc J 1989;140:1047-53.
96. Yu VL, et al. Legionnaires disease: new clinical perspective from a prospective pneumonia study. Am J Med 1982; 73:357-61.
97. Stout J, Yu VL, Vickers RM, Shonnard J. Potable water supply as the hospital reservoir for Pittsburgh pneumonia agent. Lancet 1982;1:471-2.
98. Sabria M, Campins M. Legionnaire'disease: update on epidemiology and management options. Am J Respir Med 2003; 2:23543.
99. Ortolano GA, Mc Alister MB, Angelbeck JA, et al. Hospital water point-of-use filtration: A complementary strategy to reduce the risk of nosocomial infection. Am J Infect Control 2005; 33:S1-S19.
100. Venezia RA, Agresta MD, Hanley EM, Urquhart K, Schoonmaker D. Nosocomial legionellosis associated with aspiration of nasogastric feedings diluted in tap water. Infect Control Hosp Epidemiol 1994;15:529-33.
101. Darelid J, Lofgren S, Malmvall BE.Control of nosocomial Legionnaires' disease by keeping the circulating hot water temperature above 55 degrees C: experience from a 10-year surveillance programme in a district general hospital. J Hosp Infect 2002;50:213-9.
102. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia-outcome correlations in a prospecdw study of 200 patients. Am J Med 1989; 87: 540-6.
103. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992, 36: 2639-44.
104. Sandiumengue A, Diaz E, Bodi M, Rello J. Therapy of ventilator-associated pneumonia- A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med. 2003; 29: 876-83.
105. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef M. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
106. Lee CM, Lin H K, Liu C P et al. Treatment of pandrug resistant Acinetobacter baumannii. Scand J Infect Dis 2005;37:195-9.
107. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43:S89-94.
108. Montero A, Ariza, Corballa X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004;54:1085-91.
109. Cisneros-Herreros JM, Garnacho-Montero J, Pachon-Ibanez ME-nocosomial pneumonia due to Acnetobacter baumannii Enferm Infecc Microbiol Clin 2005;23 suppl 3:46-51.
110. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
111. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter Species. Clin Infect Dis 2006;43:S95-9.
112. Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46.
113. Pedro-Botet ML, Yu V. Tratment and prevention of Legionella infection. UpToDate®. (Accessed April 23, 2006, at http://patients.uptodate.com/ print.asp?print,=true&file=pulm_inf/6738)
114. Vergis EN, Indorf A, File T, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000;160:1294-300.
115. Blazquez Garrido RM, Espinosa Parra FJ, Frances L, et al. Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005;40:800-6.
116. Gruson D, Hilbert G, Vargas F, Valentino R, Bebear C, Allery A, Bebear C, Gbikpi-Benissan G, Cardinaud JP, Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic resistant gram-negative bacteria. Am J Respir Crit Care Med 2000;162:837-43.
117. Ferrer M, Ioanas M, Torres A. Evaluation of non-responding patients with ventilator-associated pneumonia. In: Vincent JL (Ed.). Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag, Heidelberg (Germany), 2002: 365-375.
118. Lowenkron S, Fein A. The 10 most common questions about non-resolving pneumonia. Clin Pulm Med 1995; 2:8897.
119. Kuru T, Lynch JP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999;20:623-51.
120. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001; 85:1511-30.
121. Rello J, Mariscal D, March F, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998;157:912-6.
122. Silver DR, Cohen IL, Weinberg PF. Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. Chest 1992;101:194-8.
123. Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-29.
124. Rowe S, Cheadle WG. Complications of nosocomial pneumonia in the surgical patient. Am J Surg 2000; 179:63-8.
125. Craven D. Preventing ventilator-associated pneumonia in adults. Chest 2006;130:251-60.
126. Berwick DM, Calkins DR, McCamnon, et al. The 100.000 Lives Campaign: setting a goal and a deadline for improving health care quality. JAMA 2006;295:324-7.
127. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.